Camberlogo1 (Camberlogo1)
Sildenafil Tablet, Film Coated
Product Images NDC 50090-5415
14 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 50090-5415). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Camberlogo2 (Camberlogo2)
Sildenafilfigure7 (Sildenafilfigure7)
A bar graph showing the percentage of patients reporting improvement across different treatment groups: Placebo, Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. The graph illustrates increasing improvement percentages from placebo to the highest dose of Sildenafil Citrate tablets.*
Label Image (Lbl500905415)
Sildenafil 50 mg film-coated tablets label from A-S Medication Solutions showing the product name, strength, dosage form, lot number, storage instructions (store at 68 to 77 degrees Fahrenheit), and package size of 10 tablets. The label also includes a QR code and dosing instructions to see the package insert.*
Sildenafilfigure1 (Sildenafilfigure1)
A line graph comparing systolic blood pressure (mmHg) over 24 hours post-dose between Sildenafil 100 mg and placebo groups. The x-axis represents time post dose in hours, and the y-axis indicates systolic blood pressure changes from pre-dose values.*
Sildenafilfigure2 (Sildenafilfigure2)
A line graph comparing the change in a measured variable over time (minutes) for two treatments: placebo and sildenafil 25 mg. The graph shows time on the horizontal axis and change in the measured variable on the vertical axis, with sildenafil data represented by a blue line and placebo by a black line, illustrating differences in their effects over the time course.*
Sildenafilfigure3 (Sildenafilfigure3)
A line graph comparing the percentage change in a variable over time post-dose (hours) for two treatments: Dronedarone plus placebo and Dronedarone plus Sildenafil 50 mg. The graph includes data points plotted along the time axis from 0 to 8 hours, showing trends for each treatment group.*
Sildenafilfigure4 (Sildenafilfigure4)
A line graph showing the effect of Doxazosin combined with Sildenafil 100 mg versus Doxazosin combined with Placebo over time after dosing, measured in hours. The y-axis represents a variable with values ranging roughly from -50 to 40, displaying how the response changes from baseline over an 8-hour period.*
Sildenafilfigure5 (Sildenafilfigure5)
A line graph depicting plasma concentration (ng/mL) of the drug over time post-dose (hours) for a commercial tablet treatment of Sildenafil. The x-axis shows time in hours from 0 to 24, and the y-axis shows plasma concentration levels up to 500 ng/mL, illustrating the pharmacokinetic profile with a peak concentration followed by a decline over 24 hours.*
Sildenafilfigure6a (Sildenafilfigure6a)
A bar chart depicting the percentage of patients at endpoint across different baseline scores ranging from 0 to 5. Multiple bars in varying shades (from white to black) represent categories labeled 0 through 5, showing trends in patient percentages relative to baseline scores.*
Sildenafilfigure6b (Sildenafilfigure6b)
A bar chart showing the distribution of patients by baseline score and percentage at the endpoint, with baseline scores on the horizontal axis ranging from 0 to 5 and the vertical axis representing the percentage of patients. Different bar groups correspond to categories labeled 0 through 5, indicating patient percentages at each baseline score.*
Sildenafilheterologo1 (Sildenafilheterologo1)
Sildenafilheterologo2 (Sildenafilheterologo2)
Sildenafilstructure (Sildenafilstructure)
Chemical structure diagram of the active ingredient Sildenafil, showing its molecular framework including characteristic rings and side chains.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
